Reviva Pharmaceuticals Holdi · Q2 2021 earnings

Briefing

Reported financial results for the second quarter of 2021 and summarized recent business highlights.

Reviva Pharmaceuticals reported a net loss of $2.6 million for the second quarter of 2021. The company's cash and cash equivalents totaled $35.8 million as of June 30, 2021. They closed an underwritten public offering of common stock and warrants resulting in gross proceeds of $34.5 million.

• Closed underwritten public offering of common stock and warrants resulting in gross proceeds of $34.5 million.
• Expected to initiate pivotal Phase 3 clinical trial in Schizophrenia in Q4’21.
• $35.8 Million in Cash as of June 30, 2021
• Added to Russell Microcap® Index

Headline financials

Revenue & EPS history

Reviva believes that based on the current operating plan and financial resources, the Company’s cash and cash equivalents at the quarter end June 30, 2021 will be sufficient to cover general operating expenses into the second half of 2022.